Protagonist Therapeutics股票：退出合作转型为生物医药特许权复合增长股 (NASDAQ:PTGX)

Protagonist Therapeutics (PTGX) has undergone a significant business model transformation, evolving into a royalty-driven entity within the biotechnology sector. The company now benefits from two FDA-approved drugs, which are generating consistent royalty streams. This strategic pivot allows Protagonist Therapeutics to capitalize on its research and development efforts without bearing the full commercialization costs. The shift to a royalty-based model provides a more predictable revenue outlook and potentially higher profit margins. This development is viewed positively by analysts, who recommend PTGX stock as a buy. The company's ability to secure FDA approvals and monetize its assets through royalties underscores its strong pipeline and strategic execution.